HSGX - Histogenics Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1620
-0.0716 (-30.65%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.2336
Open0.2077
Bid0.0000 x 1000
Ask0.0000 x 2900
Day's Range0.1500 - 0.2095
52 Week Range0.1500 - 57.0000
Volume30,291,502
Avg. Volume227,566
Market Cap255,423
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Histogenics Corporation Announces Approval of Merger by Stockholders at Special Meeting

    Histogenics Corporation (HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with Ocugen, Inc. (“Ocugen”) were approved by Histogenics’ stockholders at a special meeting held on September 26, 2019. As previously announced, the proposed merger will create a public company under which the stockholders of Ocugen will become majority holders of the combined company. The proposed merger remains subject to further customary closing conditions and regulatory approvals.

  • GlobeNewswire

    Histogenics Corporation Announces Adjournment of its Special Meeting to Thursday, September 26, 2019

    BOSTON, Sept. 12, 2019 -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it convened and then adjourned, without conducting any.

  • GlobeNewswire

    Histogenics Corporation Announces Intent to Convene and Adjourn Its Special Meeting

    Histogenics Corporation (HSGX) (the “Company” or “Histogenics”) today announced that it intends to convene and then adjourn, without conducting any business, its special meeting of stockholders (the “Special Meeting”) to be held with respect to its proposed merger with Ocugen, Inc. (“Ocugen”) pursuant to the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019, as amended (the “Merger Agreement”), by and among the Company, its wholly-owned subsidiary, Restore Merger Sub, Inc. (“Merger Sub”) and Ocugen, which provides for the merger (the “Merger”) of Merger Sub with and into Ocugen. The Special Meeting is being adjourned in order to solicit additional proxies for the proposals to be presented at the Special Meeting.

  • ACCESSWIRE

    How Will Histogenics Shareholders Fare in the Merger with Ocugen

    NEW YORK, NY / ACCESSWIRE / April 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (HSGX), a clinical-stage company, focuses on the development of restorative cell therapies. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. On April 8th, the company announced that they have entered into a definitive merger agreement with Ocugen.

  • GlobeNewswire

    Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

    Histogenics Corporation (HSGX) and Ocugen, Inc., a privately held clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today jointly announced that they have entered into a definitive merger agreement under which the stockholders of Ocugen will become the majority owners of Histogenics’ outstanding common stock upon the close of the merger. The proposed merger will result in a combined publicly-traded, clinical-stage biopharmaceutical company operating under the Ocugen name.

  • ACCESSWIRE

    Biotech Bounce Just Getting Started

    HENDERSON, NV / ACCESSWIRE / February 20, 2019 / Biotech may have had a hard 2018, but the sector is making up for lost time at the start of this year. This may be just getting started as many fund managers ...

  • GlobeNewswire

    Jonathan Lieber Joins Danforth Advisors as Managing Director

    Danforth Advisors, LLC, a consulting firm providing operational accounting and finance support, together with CFO services, for private and public life science companies, today announced the appointment of Jonathan Lieber as Managing Director. With over 25 years of life science experience as a CFO and investment banker, Jon brings deep expertise to the role in service of clients at all stages of growth. “We hold ourselves to the highest standards of talent in the business, and Jon is no exception.

  • ACCESSWIRE

    Biotech Stocks on the Rise

    HENDERSON, NV / ACCESSWIRE / January 31, 2019 / With the IBB getting set to cap off its most bullish month in a while, the biotech industry could be in store for a major renaissance in 2019. Below are ...

  • ACCESSWIRE

    Best Ways to Play Biotech Rally

    HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of ...

  • ACCESSWIRE

    The Next Big Biotech Breakout

    HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data ...

  • ACCESSWIRE

    4 Healthcare Stocks To Watch On Friday (1/4/19)

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday. Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share.

  • GlobeNewswire

    Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway

    WALTHAM, Mass., Dec. 21, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), today provided an update on the NeoCart regulatory pathway based on discussions with the.

  • GlobeNewswire

    Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway

    WALTHAM, Mass., Nov. 29, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.

  • GlobeNewswire

    New Research Coverage Highlights Intersections, PRGX Global, Ecology and Environment, Histogenics, SeaChange International, and TransAct Technologies — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results

    WALTHAM, Mass., Nov. 08, 2018 -- ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA Submission ‒‒ October 2018 Financing Expected to.

  • GlobeNewswire

    Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

    WALTHAM, Mass., Nov. 01, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.

  • ACCESSWIRE

    What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price

    NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (HSGX) is a clinical-stage company, focuses on the development of restorative cell therapies. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. On September 5, 2018 HSGX announced that its Phase III clinical trial did not meet one of its primary endpoints, a measurement of pain and knee function after a year compared to microfracture surgery.

  • ACCESSWIRE

    Today’s Research Reports on Stocks to Watch: Immune Design and Histogenics

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Immune Design Corp. plummeted on the news that it is discontinuing a cancer vaccine program. Shares of Histogenics saw gains of over 12% as the company closed on a previously announced underwritten public offering. Immune Design Corp. shares closed down nearly 33.7% on Friday with about 3.3 million shares traded.